A Clinical Study of Intravenous Immunoglobulin

The following list is incomplete. A complete list is in the protocol. Inclusion Criteria: * Ages 3 to 75 years and weigh at least 27 kg. * Confirmed clinical diagnosis of a Primary Immune Deficiency disease including hypogammaglobulinemia, preferably with documented antibody deficiency, or agammaglobulinemia. * Has been receiving licensed IGIV for at least 3 months prior to this study. * Trough IgG levels, dose of IGIV, and treatment intervals for the last 2 consecutive licensed IGIV treatments must be documented. * The subject or legal guardian has signed the informed consent form. If appropriate, the subject has signed a child assent form. * The subject or legal representative has signed the HIPAA declaration. Exclusion Criteria: * Subjects with isolated IgG subclass deficiency or specific antibody deficiency without hypogammaglobulinemia will not be eligible. * The subject has a history of hypersensitivity or persistent or repeated adverse reactions to human immunoglobulin. * The subject has selective IgA deficiency, history of reaction to products containing IgA, or is known to have antibodies to IgA. * The subject is currently participating, or has participated within the previous 30 days, in another clinical study of an investigational product or device. * The subject is pregnant or is nursing. Women of childbearing potential must agree to using a method of contraception. * The subject has had an acute bacterial infection within 28 days of screening. * The subject i…